← boardnext 2027-12
INTS
Intensity Therapeutics, Inc.distress 4/10 · elevated risk$4.42+1%today-87% from 52w high
Lead: Sarcoma
Revenue
pre-revenue
Liquidity
$28M
Runway
3.1 yrs
Shares 1y
-94%
Price & events
-56.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.7%
1D
-9.8%
1W
+10.5%
1M
-17.1%
3M
-55.4%
6M
-44.7%
1Y
-96.3%
2Y
—
5Y
-97.0%
All
Overview
- Market Cap
- $11.95M
- Volume
- 949
- 52 Week Range
- $3.62 – $33.00
- Total Shares
- 2.70M
- Float Shares
- 2.48M
- Short %
- 4.90%
- % Held by Insiders
- 4.55%
- % Held by Institutions
- 7.01%
- RVOL
- 0.02x
- Beta
- 3.05
Pipeline stages · 1 programs
INT230-6, Eribulin, Trabectedin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-12 Estimated 50% readout ~2028-02-14 | Phase 3 | INT230-6, Eribulin, Trabectedin | Sarcoma,Soft Tissue | — | active not recruiting |
Catalyst news & presentations · 1
- 2025-09-10enrollment delayINT230-6 · Enrollment paused in Cohort A due to localized skin irritation; adjustments to be implemented before reopeningSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-08-20BenchmarkSpeculative Buy
- 2025-08-12Brookline CapitalHold → Buy
- 2025-01-13Alliance Global PartnersBuy
- 2024-11-21HC Wainwright & Co.Buy
- 2024-10-31HC Wainwright & Co.Buy
- 2024-07-11BenchmarkSpeculative Buy
Competitors — Sarcoma
- MRKMerck & Co., Inc.$318.8B · D3
- NVSEFNOVARTIS AG$292.0B · D3
- GSKGSK plc$217.0B · D1
- AMGNAMGEN INC$195.4B · D3
- INBXInhibrx Biosciences, Inc.$1.2B · D3
- KURAKura Oncology, Inc.$917M · D5
- OSTXOS Therapies Inc$69M · D7
- NMADNOMAD POWER SOLUTIONS, INC.$59M · D8
- ADAPYAdaptimmune Therapeutics PLC$45M · D7
- ACTUACTUATE THERAPEUTICS, INC.$31M · D8
Recent news
- 2026-07-22Intensity Therapeutics (INTS) Proxy filing Summary - Quartr
- 2026-07-21Intensity Therapeutics (INTS) Q1 2026 earnings summary - Quartr
- 2026-07-20Director Mark Goldberg awarded 5,500 options at Intensity Therapeutics (INTS) - Stock Titan
- 2026-07-20Intensity Therapeutics (INTS) awards director 5,500 options at $4.90 strike - Stock Titan
- 2026-07-20Intensity Therapeutics grants 5,500-share option to director | INTS Insider Trading - Stock Titan
- 2026-07-20Intensity Therapeutics (INTS) director awarded 5,500 stock options at $4.90 - Stock Titan
- 2026-07-20Intensity Therapeutics (INTS) grants 11,000 stock options to accounting officer - Stock Titan
- 2026-07-20Intensity Therapeutics (INTS) awards CFO 34,000 stock options at $4.90 - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.